Claret Medical® has closed a $14.5million funding round that it says will support market access programs for the Sentinel® Cerebral Protection System.
Serial visitor to our pages, Claret Medical’s Sentinel Cerebral Protection System is the first FDA-cleared cerebral protection device for transcatheter aortic valve replacement (TAVR).
The company has announced that its Series C financing was led by Lightstone Ventures, with participation from existing investors Easton Capital, HealthCor Partners, Incept LLC and Sante Ventures.
The company will use the proceeds to support market access programs, research and development for next generation products, and expansion of the commercial organization to build upon the successful controlled commercial release of the company’s Sentinel Cerebral Protection System in the U.S.
Since the company’s Series B round in 2014, Claret Medical has pursued a structured study program of the Sentinel device involving three randomized studies and more than 2,300 patients, including its U.S. SENTINEL pivotal trial and a large-scale, real-world trial. It has also gained FDA clearance and successfully commercialized Sentinel in leading TAVR centers across Europe, selected Asia Pacific countries and, most recently, the U.S. To date, more than 5,000 patients have benefited from the use of Claret Medical’s cerebral protection technology during their cardiovascular procedures.
“We appreciate our investors’ continued confidence in the large market opportunity presented by our technology,” said Claret Medical CEO Azin Parhizgar, PhD. “Our ongoing investment in a broad clinical program has shown that Sentinel is safe, easy to use and highly effective in reducing periprocedural TAVR stroke by 70 percent. We look forward to continuing to work with leading TAVR centers around the country to integrate Protected TAVR using the Sentinel into their programs to enhance patient safety.”
Source: Claret Medical, Inc.